search
Back to results

Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)

Primary Purpose

Postprandial Distress Syndrome

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
placebo
Xiang-sha-liu-jun granules
Sponsored by
Xiyuan Hospital of China Academy of Chinese Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postprandial Distress Syndrome

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • i)Aging between 18 and 75 years, able to read and write Chinese;
  • ii)have a TCM diagnosis of spleen deficiency and qi stagnation pattern;
  • iii) Having normal esophagogastroduodenoscopy results within 6 months;
  • iv) Having normal liver and renal function confirmed by blood tests within 3 months;
  • v) Being diagnosed as PDS of FD by a specialist consultation;
  • vi)Receiving no other treatments during the study;
  • vii)Voluntarily agreeing with the study protocol and signing a written informed consent.

Exclusion Criteria:

  • i)Having peptic ulcer or gastroesophageal reflux disease confirmed by esophagogastroduodenoscopy;
  • ii) Having obvious signs of irritable bowel syndrome;
  • iii) Having alarm symptoms (weight loss, black or tar stool, or dysphagia);
  • iv) Having serious structural disease (disease of heart, lung, liver or kidney) or mental illness;
  • v) Having had surgery related with the gastrointestinal tract, except for appendectomy more than six months ago;
  • vi) Pregnant or breastfeeding;
  • vii) Being taking drugs which may affect the gastrointestinal tract; a minimum wash-out period of two weeks is required before participating in the trial;
  • viii) Having a problem of malabsorption or maldigestion;
  • ix) Having a history of allergies to the studied drugs and food;
  • x) Having difficulties in attending the trial (such as paralysis, serious mental illness, dementia, renal diseases, stroke, coronary atherosclerotic heart diseases, diabetes or mental diseases, illiteracy);
  • xi) Unwilling to sign the informed consent.

Sites / Locations

  • the first hospital affiliated to Guangzhou university of Chinese medicineRecruiting
  • Wuhan integrated TCM and western medicine hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

placebo

Xiang-sha-liu-jun granules

Arm Description

Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.

Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.

Outcomes

Primary Outcome Measures

change of postprandial discomfort severity Scale

Secondary Outcome Measures

global impression scale
SF-36 questionnaire
gastric emptying
Gastric emptying is related with several hormones such as CCK and ghrelin.

Full Information

First Posted
April 27, 2016
Last Updated
May 4, 2016
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Collaborators
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Wuhan Integrated TCM and Western Medicine Hospita
search

1. Study Identification

Unique Protocol Identification Number
NCT02762136
Brief Title
Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)
Official Title
Xiang-sha-liu-jun Granules as an Herbal Formula for the Treatment of Postprandial Distress Syndrome(PDS): a Prospective, Double-blinded, Randomized and Placebo-controlled,Three-center Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Unknown status
Study Start Date
August 2015 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
April 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Collaborators
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Wuhan Integrated TCM and Western Medicine Hospita

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Functional dyspepsia (FD), which is one of the most common gastrointestinal disorders with high disease burden. Postprandial distress syndrome (PDS) is a common subtype of FD. Although the effectiveness of Chinese herbal formula of Xiang-sha-liu-jun granule (XSLJG) for alleviating PDS symptoms has been assessed in previous studies, more convinced evidence of randomized placebo-controlled study is needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postprandial Distress Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
216 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
Arm Title
Xiang-sha-liu-jun granules
Arm Type
Active Comparator
Arm Description
Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Type
Drug
Intervention Name(s)
Xiang-sha-liu-jun granules
Intervention Description
The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
Primary Outcome Measure Information:
Title
change of postprandial discomfort severity Scale
Time Frame
Postprandial Discomfort Severity Scale at baseline, 2 weeks, and 4 weeks during oral administration of medicine
Secondary Outcome Measure Information:
Title
global impression scale
Time Frame
global impression scale at baseline, 2 weeks, and 4 weeks during oral administration of medicine
Title
SF-36 questionnaire
Time Frame
SF-36 questionnaire at baseline, 2 weeks, and 4 weeks during oral administration of medicine
Title
gastric emptying
Description
Gastric emptying is related with several hormones such as CCK and ghrelin.
Time Frame
gastric emptying will be assessed at baseline and 4 weeks during oral administration of medicine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: i)Aging between 18 and 75 years, able to read and write Chinese; ii)have a TCM diagnosis of spleen deficiency and qi stagnation pattern; iii) Having normal esophagogastroduodenoscopy results within 6 months; iv) Having normal liver and renal function confirmed by blood tests within 3 months; v) Being diagnosed as PDS of FD by a specialist consultation; vi)Receiving no other treatments during the study; vii)Voluntarily agreeing with the study protocol and signing a written informed consent. Exclusion Criteria: i)Having peptic ulcer or gastroesophageal reflux disease confirmed by esophagogastroduodenoscopy; ii) Having obvious signs of irritable bowel syndrome; iii) Having alarm symptoms (weight loss, black or tar stool, or dysphagia); iv) Having serious structural disease (disease of heart, lung, liver or kidney) or mental illness; v) Having had surgery related with the gastrointestinal tract, except for appendectomy more than six months ago; vi) Pregnant or breastfeeding; vii) Being taking drugs which may affect the gastrointestinal tract; a minimum wash-out period of two weeks is required before participating in the trial; viii) Having a problem of malabsorption or maldigestion; ix) Having a history of allergies to the studied drugs and food; x) Having difficulties in attending the trial (such as paralysis, serious mental illness, dementia, renal diseases, stroke, coronary atherosclerotic heart diseases, diabetes or mental diseases, illiteracy); xi) Unwilling to sign the informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
xudong Tang, Ph.D
Phone
+86-10-62835001
Email
txdly@sina.com
First Name & Middle Initial & Last Name or Official Title & Degree
fengyun Wang, Ph.D
Phone
+86-10-62835001
Email
wfy811@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
xudong Tang, Ph.D
Organizational Affiliation
xi yuan hospital
Official's Role
Study Chair
Facility Information:
Facility Name
the first hospital affiliated to Guangzhou university of Chinese medicine
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510405
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
suiping huang, Ph.D
Facility Name
Wuhan integrated TCM and western medicine hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhaohong Shi, Ph.D

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
31011363
Citation
Zhang J, Wang X, Shi X, Xie J, Zhang M, Ma J, Wang F, Tang X. Combination of 15 lipid metabolites and motilin to diagnose spleen-deficiency FD. Chin Med. 2019 Apr 15;14:16. doi: 10.1186/s13020-019-0238-9. eCollection 2019.
Results Reference
derived

Learn more about this trial

Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)

We'll reach out to this number within 24 hrs